The importance of histology when evaluating the cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced non-small cell lung cancer

Category Primary study
JournalJournal of Clinical Oncology
Year 2009
This article has no abstract
Epistemonikos ID: 532eb928afeebb582f8e40067b4a31bac1b8d9ed
First added on: Mar 01, 2025